- Conditions
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
- Interventions
- Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non Small Cell Lung Cancer, KRAS Gene Mutation
- Interventions
- Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG, Trametinib 2 mg, Ponatinib 15 MG, Ponatinib 30 MG
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Myeloid Leukemia, Chronic, Chronic Phase
- Interventions
- Ponatinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 16
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 12 more
- Conditions
- Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Rochester, New York